Neurodegenerative diseases damage the nervous system and lead to a variety of complex progressive chronic issues. Alzheimer’s disease (AD) is one such case. The most common form of dementia is a degenerative disorder of the brain that leads to memory loss, confusion, and behavioral changes. The main drug classes currently used to treat AD are acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. In this study, we investigated the inhibitory effects of a series of newly synthesized compounds of 2-hydroxy-N-phenylbenzamide derivatives on AchE and BchE, using molecular modeling approaches such as molecular dynamics and bioisosteric replacement to treat or reduce Alzheimer’s disease.
The best docking complexes, L18 and L6′, were used as simulation inputs to evaluate the stability of the complex (protein–ligand), using potential energy as a function of time. These results were verified using molecular dynamics simulations, demonstrating the strength of both complexes.
Furthermore, we found that the bioisosteric replacement method successfully proposed two novel analogs of each compound (L18 and L6′) with low energy scores and similar biological activity by replacing molecular substructures with similar chemical groups.
All these methods allow us to identify new inhibitors that have potential against this disease and can be suggested as new drugs against Alzheimer’s disease.
Author Contributions
Data collection, software, formal analysis, and first draft of the manuscript were prepared by F.H. All authors commented on previous versions of the manuscript. I.D. contributed to the conceptualization and supervision of the study. N.M., I.D. and R.K. contributed to the interpretation of docking and ADME-T studies. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
All the data in the article are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare that they have no conflict of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).